checkAd

     133  0 Kommentare HCA Healthcare’s Sarah Cannon Cancer Institute Implements New Outpatient Model for CAR T-cell Therapy

    HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that the Sarah Cannon Cancer Institute (SCCI) of HCA Healthcare has successfully established an integrated management process that safely transitioned more than 75% of HCA Healthcare’s CAR T-cell therapy patients into an outpatient setting for monitoring. The program model resulted in more than 1,200 hospital bed days saved for the first 100 patients of the program compared to historical results, and approximately 20% of patients avoided hospitalization altogether.

    Piloted at four Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN) sites and using new technology for at-home patient monitoring, trained outpatient clinical teams, including nurses, clinical pharmacists, advanced practice professionals, social workers and case managers, have created a model to help reduce the time patients spend in the hospital after treatment during the typical two-week monitoring period.

    “Patients heal better outside the hospital if they can get these complicated therapies, which carry risk for significant complications, safely in the outpatient setting,” said Dr. Navneet Majhail, physician-in-chief of blood cancers, Sarah Cannon Transplant & Cellular Therapy Network. “We have leveraged technology and developed clinical pathways to care for patients receiving CAR T-cell therapies. Our clinical teams have accomplished this by standardizing care across a network of several cell therapy programs. In addition to patient benefits, their work has helped us better anticipate and meet the increasing demand for cell therapies as we continue to innovate our care delivery models to enhance timely access for these important treatments.”

    Chimeric antigen receptor T-cell therapy, also known as CAR T-cell therapy, is an immunotherapy designed to program a patient’s immune system to recognize and fight cancer. During the CAR T-cell treatment process, T-cells are drawn from a patient’s blood and genetically modified to recognize the patient’s cancer cells when reinfused. Because these oncology patients require intensive, specialized and time-sensitive care, they are closely monitored for any complications and have historically required inpatient hospitalization for up to two weeks post infusion.

    Seite 1 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen

    HCA Healthcare’s Sarah Cannon Cancer Institute Implements New Outpatient Model for CAR T-cell Therapy HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that the Sarah Cannon Cancer Institute (SCCI) of HCA Healthcare has successfully established an integrated management process that safely transitioned …

    Schreibe Deinen Kommentar

    Disclaimer